In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. I don't know. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. And there are often rumors of other deals that never materialize. One of the catalysts that could work in its favor is deal optimism. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. . ET, Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug, 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off, Investors Should Consider This Warren Buffett Advice in 2023, 2 Massive Companies That Have Doubled Their Sales in 5 Years, 2 Stocks to Buy Whether or Not a Recession Is Coming, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? Copyright 2023 InvestorPlace Media, LLC. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. The quest behind the drive is to fill potential gaps in the pipeline. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. To read this article on Zacks.com click here. Keith Speights owns shares of Vertex Pharmaceuticals. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Healthcare. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. The Company submitted a Marketing Authorization Application to the. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. 7. (2016). All rights reserved. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Today, you can download 7 Best Stocks for the Next 30 Days. Keep track of M&A as it happens with this database. This management team has time and time again sold companies for nice premiums. All rights reserved. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. Brian, what are some acquisitions that you'd like to. Speights: Yeah. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Acquisitions are back in full swing in the sector. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Go and get the Biotech Investments HOT STOCK REPORT. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Now, let's take a speculative twist in our discussion about acquisitions. If you have an ad-blocker enabled you may be blocked from proceeding. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. Trading stocks is risky -- always be sure to know and understand your risk tolerance. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. 06-01-2023. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. BioSpace is covering all the key announcements all week. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. No. Antares Pharma. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. Which company is going to get bought? It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. (Source: EY 2019 M&A Firepower Report) 1. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Dealmaking is essential to the business of drug development. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. But I think there's also a good fit on Seagen's pipeline too. Example: +water -Europe The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. Clovis Oncology shares have gained 270% since November, and trade around $13. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. In case of a buyout, investors often benefit of a massive premium. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. Stay on top of what's happening at JPM. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Who will buy? Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. Biotech M&A With a Slow Start in 2020: More Deals to Follow? *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. Alexion Pharmaceuticals. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. I own Seagen. Sanofi has been quite active on the M&A front this year. Here's a look at the 10 top takeover targets. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. 2023 InvestorPlace Media, LLC. Additionally, Dan is a Scientist and inventor. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Freight. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. PwC. Date Acquirer Co. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. Nasdaq The company is also developing CRISPR gene-editing therapeutic candidates for DMD. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Making the world smarter, happier, and richer. The pipeline progress has been encouraging. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. The Motley Fool recommends Biogen and Gilead Sciences. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. Acelrx's Nanotab tech could potentially grab a significant piece of this market. Scott has long positions in 3 companies mentioned in this article. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. We believe there is merit to the current rumors surrounding AcelRx. That's right -- they think these 10 stocks are even better buys. AcelRx (ACRX). They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Enclose phrases in quotes. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). Is this happening to you frequently? Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. Someone is "mistaken" here. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. Best Stocks & ETFs. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. Pharma giant Pfizer recently. In the business of drug development, deals can be just as important as scientific breakthroughs. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. The first few months lived up to expectations: All of the top 10 M&A deals of January-June 2018 exceeded $1.5 billion, paced by the completion of Bayer's $63 billion buyout of Monsanto . Additionally, the database is limited to deals valued at a minimum of $50 million upfront. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . CRISPR Therapeutics CRSP is one of the leading gene-editing companies. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. Otrexyo is a registered trademark of Pfizer. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. But Brian, is there a biotech buyout that you would really like to see? Analysts, on average, see scope for about 90% upside for Mirati stock. *Stock Advisor returns as of September 17, 2021. Written by Scott Matusow. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. Scott has had the most success in trading/investing in smaller cap growth companies. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. I think that would potentially drive sales of Opdivo. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. They are my opinions only. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. Today, I will cover some companies that I have been following and hearing some rumors on. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. It was also approved in the EU. Invest better with The Motley Fool. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. It's in phase 1, so we don't really know how well it works yet. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . Alnylam stock has a market capitalization of over $20 billion. We first began to hear acquisition rumors in Antares in late 2011. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number.
Things That Weigh 60 Grams, Are Avril And Adam Levine Siblings, Does Albanese Pay Weekly, Hoover Onepwr Battery Charger Flashing Red, How Old Is Meryl Lipstein, Articles B